top of page

GPCR News 

Post: Blog2_Post

California gold rush for Sosei Heptares

November 2021

"Cambridge’s Japanese-owned life sciences company Sosei Heptares has clinched a lucrative deal with California-based NASDAQ-quoted business Neurocrine Biosciences.

The vision is to develop novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric disorders.

Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023."

0 views0 comments

Recent Posts

See All

Amgen to Acquire Chemocentryx for $4 Billion in Cash

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin